Bristol-Myers Squibb gets rated a hold, as I see future value in its clinical portfolio and pipeline, particularly ...

Shares of Bristol Myers Squibb Co. BMY shed 3.04% to $58.76 Tuesday, on what proved to be an all-around positive trading ...

Over the last three months, we've seen significantly more insider buying, than insider selling, at Bristol-Myers Squibb.

We recently compiled a list of the 12 Best Blue Chip Stocks to Buy Under $100. In this article, we are going to take a look ...

Bristol Myers Squibb (BMY) says its cancer drugs Opdivo and Yervoy improved progression-free survival in a Phase 3 trial for ...

Squibb announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended ...

Bristol-Myers Squibb (NYSE:BMY – Free Report) had its target price boosted by Citigroup from $60.00 to $65.00 in a report published on Tuesday,Benzinga reports. They currently have a neutral rating on ...

Bristol Myers on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Breyanzi for the treatment of adults with relapsed or refractory ...

Bristol-Myers Squibb (NYSE:BMY), a global biopharmaceutical company with a market capitalization of nearly $120 billion, finds itself at a critical juncture as it navigates a complex landscape of ...

Bristol Myers (BMY) announced the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has ...

We recently published a list of Jim Cramer Breaks Silence On DeepSeek AI Sell-Off & Discusses These 12 Stocks. In this ...

Bristol-Myers Squibb Company (BMY) is one of the leading biopharmaceutical companies focused on developing treatments for ...